Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 43

1.

The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man.

Preston GC, Brazell C, Ward C, Broks P, Traub M, Stahl SM.

J Psychopharmacol. 1988 Jan;2(2):67-79. doi: 10.1177/026988118800200202.

PMID:
22155841
2.

Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor.

Snyder PJ, Bednar MM, Cromer JR, Maruff P.

Alzheimers Dement. 2005 Oct;1(2):126-35. doi: 10.1016/j.jalz.2005.09.004.

PMID:
19595845
3.

Drug discovery in dementia: the role of rodent models.

Van Dam D, De Deyn PP.

Nat Rev Drug Discov. 2006 Nov;5(11):956-70. Review.

PMID:
17080031
4.
5.

Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women.

Dumas J, Hancur-Bucci C, Naylor M, Sites C, Newhouse P.

Neuropsychopharmacology. 2006 Sep;31(9):2065-78. Epub 2006 Feb 15.

6.

Effects of selegiline alone or with donepezil on memory impairment in rats.

Takahata K, Minami A, Kusumoto H, Shimazu S, Yoneda F.

Eur J Pharmacol. 2005 Aug 22;518(2-3):140-4.

PMID:
16061218
7.

The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.

Lieben CK, Blokland A, Sik A, Sung E, van Nieuwenhuizen P, Schreiber R.

Neuropsychopharmacology. 2005 Dec;30(12):2169-79.

8.

Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study.

Beglinger LJ, Tangphao-Daniels O, Kareken DA, Zhang L, Mohs R, Siemers ER.

J Clin Psychopharmacol. 2005 Apr;25(2):159-65.

PMID:
15738747
9.

CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.

Youdim MB, Buccafusco JJ.

J Neural Transm (Vienna). 2005 Apr;112(4):519-37. Epub 2005 Jan 24. Review.

PMID:
15666041
11.

AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors.

Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R.

Psychopharmacology (Berl). 2004 Apr;172(4):375-83. Epub 2004 Jan 15.

PMID:
14727003
12.

Detecting dementia: novel neuropsychological markers of preclinical Alzheimer's disease.

Blackwell AD, Sahakian BJ, Vesey R, Semple JM, Robbins TW, Hodges JR.

Dement Geriatr Cogn Disord. 2004;17(1-2):42-8. Epub 2003 Oct 13.

PMID:
14560064
13.
15.

Behavioral characterization of mild cognitive impairment.

Collie A, Maruff P, Currie J.

J Clin Exp Neuropsychol. 2002 Sep;24(6):720-33.

PMID:
12424647
16.

A computer-assisted cognitive test battery for aged monkeys.

Buccafusco JJ, Terry AV Jr, Murdoch PB.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):179-85.

PMID:
12212778
17.

Multiple central nervous system targets for eliciting beneficial effects on memory and cognition.

Buccafusco JJ, Terry AV Jr.

J Pharmacol Exp Ther. 2000 Nov;295(2):438-46.

18.

The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment.

Collie A, Maruff P.

Neurosci Biobehav Rev. 2000 May;24(3):365-74. Review.

PMID:
10781696
19.

Effect of rivastigmine on scopolamine-induced memory impairment in rats.

Bejar C, Wang RH, Weinstock M.

Eur J Pharmacol. 1999 Nov 3;383(3):231-40.

PMID:
10594314
20.

Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery.

Taffe MA, Weed MR, Gold LH.

Brain Res Cogn Brain Res. 1999 Oct 25;8(3):203-12.

PMID:
10556599

Supplemental Content

Support Center